Global Anthrax Vaccine Market Set to Achieve $14.5 Billion Milestone with Sustained 5.1% CAGR
The anthrax vaccine market size is expected to see strong growth in the next few years. It will grow to $14.5 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to global security challenges, emerging threats, government procurement initiatives, pandemic preparedness. Major trends in the forecast period include technological advancements, greater accessibility in developing countries, focus on next-generation vaccines, increased government stockpiling, collaborative research efforts.
Get Your Free Sample of The Global Anthrax Vaccine Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp
How have varous drivers impacted the growth of the anthrax vaccine market?
The rising prevalence of infectious diseases is expected to propel the growth of the anthrax vaccine market going forward. Infectious diseases refer to illnesses caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, which can spread directly or indirectly from one person to another, often leading to symptoms ranging from mild to severe and sometimes fatal, depending on the pathogen and the individual's immune response. The prevalence of infectious diseases is due to shifts in the demographics of the world's population, urbanization, changes in the environment and land use, and changes in human behavior. The anthrax vaccine is primarily utilized to protect against anthrax, and its potential for broader use in preventing other infectious diseases is being explored through research into its immunogenic properties and adaptability. For instance, in February 2023, according to the Council on Foreign Relations, a US-based nonprofit organization, up to 75% of newly discovered or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases had zoonotic origins. Further, worldwide, zoonoses cause 2.7 million human fatalities and 2.5 billion episodes of disease in people each year. Therefore, the rising prevalence of diseases is driving the growth of the anthrax vaccine market.
What are the primary segments of the anthrax vaccine market?
The anthrax vaccine market covered in this report is segmented –
1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine
2) By Application Type: Animal Use, Human Use
3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels
Subsegments:
1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine
2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report
Which firms are leading the anthrax vaccine market?
Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A
How will industry trends affect the trajectory of the anthrax vaccine market?
Major companies operating in the anthrax vaccine market are focused on developing innovative products and getting FDA approvals for their vaccines to ensure safety, efficacy, and availability to those at risk of exposure to anthrax. FDA approval ensures the vaccine is rigorously tested in clinical trials and proven safe for public use. This helps protect individuals from potential adverse effects. For instance, in July 2023, Emergent BioSolutions Inc., a US-based biopharmaceutical company, received approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, from the U.S. Food and Drug Administration (FDA). The approval was predicated on information from a Phase 2 trial evaluating Cyfendus's non-interference with antibacterial medications and Phase 3 clinical research comparing the immunogenicity and safety of the vaccine to BioThrax, the previous anthrax vaccine. Further, developing safer and more effective adjuvants is imperative to address reactogenicity-related problems and enhance the general efficiency of anthrax vaccines.
Which geographic trends are shaping the anthrax vaccine market, and which region has the highest market share?
North America was the largest region in the anthrax vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Anthrax Vaccine Market Report 2025 Offer?
The anthrax vaccine market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
The anthrax vaccine is a medical product designed to provide immunity against anthrax, a severe infectious disease caused by the bacterium Bacillus anthracis. The vaccine comprises an inactivated form of the anthrax bacterium or its components, stimulating the body's immune system to produce antibodies against anthrax toxins. The anthrax vaccine is typically administered through injections, with initial doses followed by booster shots to maintain immunity over time.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15511
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Comments
Post a Comment